Table S1 Study details

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Title** | **Identification of registration** | **Severity** | **Intervention groups details** | **Control group details** |
| Fingolimod in COVID-19 | NCT04280588 | Moderate or severe | Fingolimod 0.5 mg orally once daily | No intervention |
| Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) | NCT04273763 | Moderate | Bromhexine Hydrochloride Tablets + Favipiravir Tablets + Arbidol Hydrochloride Granules + Recombinant Human Interferon α2b Spray | Arbidol Hydrochloride Granules + Recombinant Human Interferon α2b Spray |
| The Clinical Study of Carrimycin on Treatment Patients With COVID-19 | NCT04286503/ChiCTR2000029867 | Moderate or severe | Basic treatment + CarrimycinMild type: 0.4g of Carrimycin tablets, p.o. after meal once a day for 7 consecutive days, followed up for observation after the end of treatment.Ordinary type: 0.4g of Carrimycin tablets, p.o. after meal once a day for 10 days, followed up for observation after the end of treatment.Severe and critical: 0.4g of Carrimycin tablets, p.o. after meal once a day for 14 consecutive days. If oral administration is not possible, the drug should be administered through a nasal feeding tube. For the combination drugs of basic treatment according to the Diagnosis and Treatment Program for 2019-nCoV(V5.0,Chinese) | Any of basic treatment + lopinavir/ritonavir tablets or Arbidol or chloroquine phosphateMild and ordinary type: 400mg/100mg, bid of lopinavir/ritonavir tablets each time; or 500mgbid of chloroquine phosphate; or 200mg tid of Arbidol for 7 consecutive days, followed up for observation after the end of treatment.Severe and critical type: 400mg/100mg, bid of lopinavir/ritonavir tablets each time; or 500mgbid of chloroquine phosphate; or 200mg tid of Arbidol for 10 consecutive days, followed up for observation after the end of treatment. For the combination drugs of basic treatment according to the Diagnosis and Treatment Program for 2019-nCoV(V5.0,Chinese) |
| Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus | NCT04252118 | Moderate or severe | Conventional treatment plus 3 times of MSCs(3.0\*10E7 MSCs intravenously at Day 0, Day 3, Day 6) | Conventional treatment |
| The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia | NCT04273529 | Moderate or severe | Thalidomide 100mg, po, qn, for 14 days | Placebo |
| Efficacy and Safety of Corticosteroids in COVID-19 | NCT04273321 | Moderate or severe | Methylprednisolone 1mg/kg/day ivgtt for 7 days | No intervention |
| The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19 | NCT04273581 | Severe | Thalidomide 100mg/d, qn for 14 days + Low-dose hormones defined as :α-interferon: nebulized inhalation, 5 million U or equivalent dose added 2ml of sterile water for injection, 2 times a day, for 7 days; Abidol, 200mg / time, 3 times a day, for 7 days; Methylprednisolone: 40mg, q12h, for 5 days. | Placebo 100mg/d, qn for 14 days + Low-dose hormones defined as :α-interferon: nebulized inhalation, 5 million U or equivalent dose added 2ml of sterile water for injection, 2 times a day, for 7 days; Abidol, 200mg / time, 3 times a day, for 7 days; Methylprednisolone: 40mg, q12h, for 5 days. |
| Mild/Moderate 2019-nCoV Remdesivir RCT | NCT04252664 | Moderate | Remdesivir 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days. | Remdesivir placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days |
| Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 | NCT04287686 | Moderate | Recombinant human angiotensin-converting enzyme 2 (rhACE2) 0.4 mg/kg IV BID for 7 days (unblinded) + standard of care | Standard of care |
| The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia | NCT04261426 | Severe | Intravenous Immunoglobulin 0.5g/kg/d for 5 days + standard of care | Standard of care |
| A Prospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia | NCT04255017 | Moderate or severe | • Abidol hydrochloride 0.2g once,3 times a day, 2 weeks + Symptomatic supportive treatment• Oseltamivir 75mg once, twice a day, 2 weeks + Symptomatic supportive treatment• Lopinavir/ritonavir 500mg once, twice a day, 2 weeks + Symptomatic supportive treatment | Symptomatic supportive treatment |
| A Prospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia | NCT04254874 | Moderate or severe | Abidol Hydrochloride:0.2g once, 3 times a day, two weeks; combined with Interferon (PegIFN-α-2b) atomization: 45ug, add to sterile water 2ml, twice a day, two weeks | Abidol hydrochloride 0.2g once, 3 times a day, two weeks + Standard symptomatic support therapy |
| Immunoregulatory Therapy for 2019-nCoV | NCT04268537 | Severe | • PD-1 blocking antibody 200mg iv, one time + Standard treatment is according to the protocol of treatment of 2019-nCoV infection • Thymosin 1.6 mg sc qd, last for 5 days + Standard treatment is according to the protocol of treatment of 2019-nCoV infection | Standard treatment is according to the protocol of treatment of 2019-nCoV infection |
| Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia | NCT04273646 | Severe | Umbilical cord mesenchymal stem cells (UC-MSCs) 4 times (0.5\*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7) + Conventional treatment | Placebo (4 times of cell-free stem cell suspension, saline containing 1% human albumin, intravenously at Day 1, Day 3, Day 5, Day 7) + Conventional treatment |
| Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus | NCT04260594/ChiCTR2000029621 | Moderate | Arbidol hydrochloride tablets 2 tablets/time, 3 times/day for 14-20 days + basic treatment (used by the investigator was based on the condition of the patient) |  Basic treatment |
| A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia | NCT04261270 | Moderate | •ASC09F tablets: one tablet (400mg/tablet) twice a day for 14 days + Oseltamivir tablet: 75mg,once a day•Ritonavir tablet: three tablets (100mg/tablet) twice a day for 14 days + Oseltamivir tablet: 75mg, once a day | Oseltamivir 75mg, once a day |
| The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia | NCT04263402 | Moderate or severe | Methylprednisolone (<40mg/d intravenous drip for 7 days) + basic symptomatic supportive treatment | Basic symptomatic supportive treatment + methylprednisolone(40~80mg/d intravenous drip for 7 days) |
| Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection | NCT04261907/ChiCTR2000029603 | Moderate | ASC09/ritonavir (300mg/100mg tablet) one tablet each time, twice daily, for 14 days + conventional standardized treatment | Lopinavir/ritonavir tablet (200mg / 50mg tablet) two tablets each time, twice daily, for 14 days + conventional standardized treatment |
| Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients | NCT04264858 | Severe | Immunoglobulin of cured patients 0.2g/kg, ivdrip, once a day, for 3 days | γ-Globulin 0.2g/kg, ivdrip, once a day, for 3 days |
| Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia | NCT04275414 | Moderate or severe | Bevacizumab 500mg + normal saline (0.9% sodium chloride solution) 100ml, ivdrip ≥90min | Regular therapy |
| Adaptive COVID-19 Treatment Trial | NCT04280705 | Moderate or severe | 200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir for the duration of the hospitalization up to a 10 days total course | 200 mg of Remdesivir placebo administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir placebo for the duration of the hospitalization up to a 10 days total course |
| Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ) | NCT04261517 | Moderate or severe | Hydroxychloroquine 400 mg per day for 5 days, + conventional treatments | Conventional treatments |
| Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV | NCT04252274 | Moderate or severe | Darunavir and Cobicistat one tablet per day for 5 days + conventional treatments | conventional treatments |
| NK Cells Treatment for Novel Coronavirus Pneumonia | NCT04280224 | Moderate or severe | Conventional treatment plus twice a week of NK cells (0.1-2\*10E7 NK cells/kg body weight) | Conventional treatment |
| Severe 2019-nCoV Remdesivir RCT | NCT04257656 | Severe | Remdesivir 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days. | Remdesivir placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days. |
| A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia | NCT04276987 | Severe | 5 times aerosol inhalation of MSCs-derived exosomes (2.0\*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5) + Conventional treatment  |   |
| Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment | NCT04276688 | Moderate or severe | Lopinavir/ritonavir 400mg/100mg twice daily for 14 days + Ribavirin 400mg twice daily for 14 days + Interferon Beta-1B 0.25mg subcutaneous injection alternate day for 3 days | Lopinavir/ritonavir 400mg/100mg twice daily for 14 days |
| The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection | NCT04252885 | Moderate or severe | •Ordinary treatment + lopinavir (200mg) and ritonavir (50mg) (oral, q12h, every time 2 tablets of each, taking for 7-14 days)•Ordinary treatment + arbidol (100mg) (oral, tid, 200mg each time, taking for 7-14 days) | Ordinary treatment |
| Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia | NCT04269525 | Severe | UC-MSCs infusion intravenously (3.3 \* 107 cell number / 50ml / bag, 3 bags each time) on day 1, day 3, day 5, and day 7, 1 time each day | NR |
| Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia | NCT04275245 | Moderate or severe | 10mg Meplazumab by intravenous infusion, every day for 2 days | NR |
| Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure | NCT04244591 | Severe | Methylprednisolone 40 mg q12h for 5 days | Standard care |
| A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection | NCT04282902 | Moderate or severe | Pirfenidone orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer | Standard treatment |
| A randomized, open-label, blank-controlled trial for the efficacy and safety of lopinavir-ritonavir and interferon-alpha 2b in hospitalization patients with novel coronavirus pneumonia (COVID-19) | ChiCTR2000029308 | Moderate or severe | Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and 50 mg of ritonavir), twice a day, 2 tablets at a time + interferon-α2b | Conventional standardized treatment |
| Adjunctive Corticosteroid Therapy for Patients with Severe Novel Coronavirus Pneumonia (COVID-19): a Randomized Controlled Trial | ChiCTR2000029386 | Severe | Methylprednisolone, intravenous injection, 1-2mg/kg·d for 3 days. | No intervention |
| Comparison of efficacy and safety of three antiviral regimens in patients with mild to moderate novel coronavirus pneumonia (COVID-19): a randomized controlled trial | ChiCTR2000029387 | Moderate | •Ribavirin + Interferon alpha-1b•lopinavir / ritonavir + interferon alpha-1b•Ribavirin + LPV/r + Interferon alpha-1b | NR |
| A real-world study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) | ChiCTR2000029468 | Moderate or severe | Lopinavir/litonavir (LPV/r) + emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) in combination | Lopinavir/litonavir  |
| A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) | ChiCTR2000029539 | Moderate | Lopinavir-Ritonavir + conventional standardized treatment | Conventional standardized treatment |
| A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) | ChiCTR2000029541 | Moderate or severe | •Darunavir/cobicistat (800mg/150mg QD) + Conventional treatment containing thymosin (1.6 mg SC QOD) •Lopinavir/ritonavir (400mg/100mg bid) + Conventional treatment containing thymosin (1.6 mg SC QOD) | Conventional treatment containing thymosin (1.6 mg SC QOD)  |
| Study for the efficacy of chloroquine in patients with 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) | ChiCTR2000029542 | Moderate or severe | Chloroquine 0.5 gram every time, twice a day for a 10-day course | Conventional management |
| A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) patients who are still positive on virus detection under the current antiviral therapy | ChiCTR2000029544 | Moderate | • Baloxavir Marboxil tablets + current antiviral treatment• Favipiravir tablets + current antiviral treatment | Current antiviral treatment |
| Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) patients | ChiCTR2000029548 | Moderate | • BaloxavirMarboxil:80mg on day1,80mg on day4; and 80mg on day7 as necessary. No more than 3 times administration in total.• Favipiravir: 600 mg tid with 1600mg first loading dosage for no more than 14 days.• Lopinavir-Ritonavir: 2# (200mg/50 mg), twice daily, for 14days. | NR |
| Therapeutic effect of hydroxychloroquine on 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) | ChiCTR2000029559 | Moderate or severe | •Hydroxychloroquine 0.1 oral 2/ day•Hydroxychloroquine 0.2 oral 2/ day | Placebo (Starch pill oral 2/ day) |
| Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a randomized controlled trial | ChiCTR2000029569 | Severe | Conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group | Conventional treatment |
| Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a randomized controlled clinical trial | ChiCTR2000029572 | Severe | Conventional treatment combined with umbilical cord blood mononuclear cells group | Conventional treatment |
| A multicenter, randomized, open-label, positive-controlled trial for the efficacy and safety of recombinant cytokine gene-derived protein injection combined with abidole, lopinavir/litonavir in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) patients | ChiCTR2000029573 | Moderate or severe | • Arbidol Tablets 200mg/ time, p.o.tid.• Novaferon injection 20g/ time, atomized inhalation, tid + Arbidol Tablets 200mg/ time, p.o.tid.•Lopinavir/litonavir 500mg/100mg/ time, p.o.tid.•Arbidol Tablets 200mg/ time, p.o.tid.•Novaferon injection 20g/ time, atomized inhalation, tid + Lopinavir/litonavir 500mg/100mg/ time, p.o.tid.• Novaferon injection 20g/ time, atomized inhalation, tid + Arbidol Tablets 200mg/ time, p.o.tid. | NR |
| A prospective, single-blind, randomized controlled trial for Ruxolitinib combined with mesenchymal stem cell infusion in the treatment of patients with severe 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) | ChiCTR2000029580 | Severe | Ruxolitinib combined with mesenchymal stem cell |  Routine treatment |
| Clinical study for safety and efficacy of Favipiravir in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) | ChiCTR2000029600 | Moderate or severe | •Lopinavir and Ritonavir + alpha-Interferon atomization•Favipiravir + alpha-Interferon atomization | Alpha-Interferon atomization |
| Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP) | ChiCTR2000029606 | Moderate or severe | •Conventional treatment followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations•Artificial liver therapy + conventional treatment•Artificial liver therapy followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations + conventional treatment |  Conventional treatment (2 groups of control) |
| A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) | ChiCTR2000029609 | Moderate or severe | •Mild-moderate chloroquine phosphate•Mild-moderate Lopinavir/ritonavir•Mild-moderate combination : chloroquine phosphate plus Lopinavir/ritonavir•Severe-chloroquine phosphate•Severe- Lopinavir/ritonavir(1. Chloroquine phosphate tablet, 0.25 gram per pill, which contains chloroquine 0.155 gram; 2. Lopinavir/ritonavir tablet, each pill containing lopinavir 200mg and ritonavir 100mg ) | NR |
| Efficacy and safety of aerosol inhalation of vMIP in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a single arm clinical trial | ChiCTR2000029636 | Moderate or severe | Conventional standardized treatment and viral macrophage inflammatory protein (vMIP) atomized inhalation | NR |
| Multicenter randomized controlled trial for novel recombinant high-efficiency compound interferon in the treatment of novel coronavirus pneumonia (COVID-19) | ChiCTR2000029638 | Moderate or severe | Nebulization of novel gene recombinant super compound interferon | Nebulization of alpha-interferon |
| A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) | ChiCTR2000029656 | Moderate or severe | Standard treatment and methylprednisolone for injection | Standard treatment |
| Efficacy of therapeutic effects of hydroxycholoroquine in 2019-nCoV pneumonia (novel coronavirus pneumonia) patients | ChiCTR2000029740 | Moderate or severe | Oral intake hydroxycholoroquine 0.2 twice a day | Conventional therapy |
| Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study | ChiCTR2000029741 | Moderate | Chloroquine Phosphate | Lopinavir / Ritonavir |
| A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19) | ChiCTR2000029742 | Moderate or severe | Normal Treatment plus Sodium Aescinate for Injection(2 experimental arms: general and severe patients) | •Normal treatment plus hormonotherapy (3 control arm: general, severe and severe treated with normal treatment + hormonotherapy)•Normal Treatment |
| Convalescent plasma for the treatment of severe novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial | ChiCTR2000029757 | Severe | Conventional treatment and convalescent plasma therapy (intravenously infused with plasma which antibody titer is higher than 1:80, usually 200-400ml (4-5 ml/kg)) | Conventional treatment |
| Clinical study on the safety and effectiveness of Hydroxychloroquine Sulfate tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19) | ChiCTR2000029761 | Moderate or severe | •Low-dose hydroxychloroquine and conventional therapy•Medium-dose hydroxychloroquine and conventional therapy•High-dose hydroxychloroquine and conventional therapy | Conventional therapy |
| A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19) | ChiCTR2000029765 | Moderate or severe | Conventional therapy + tocilizumab | Conventional therapy |
| A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19) | ChiCTR2000029776 | Moderate | Polyinosinic-Polycytidylic Acid Injection and conventional therapy | Conventional therapy |
| Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19) | ChiCTR2000029806 | Severe | •Thymosin for injection 1.6 mg sc qd for 5 days•Camrelizumab 200 mg single dose, diluted to 100 ml intravenous infusion | Conventional treatment |
| Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) | ChiCTR2000029812 | Moderate | Conventional treatment followed by Intravenous infusion of Umbilical Cord Blood Mononuclear Cells preparations | Conventional treatment |
| Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) | ChiCTR2000029816 | Moderate | Conventional treatment followed by Intravenous infusion of Cord Blood Mesenchymal Stem Cells preparations  | Conventional treatment |
| Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) | ChiCTR2000029817 | Moderate | •High-dose NK cells (>5x10^9) and mesenchymal stem cells (>5x10^9), Intravenous infusion once every two days for a total of five times•Conventional dose NK cells (>3x10^9) and mesenchymal stem cells (>3x10^9), Intravenous infusion once every two days for a total of three times•Preventive dose NK cells (>3x10^9) and mesenchymal stem cells (>3x10^9), Intravenous infusion once every week for a total of one time | NR |
| Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) | ChiCTR2000029818 | Moderate | Conventional treatment followed by Intravenous infusion of Umbilical Cord Blood Plasma preparations | Conventional treatment |
| A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19) | ChiCTR2000029826 | Severe | Phosphoric chloroquine BID + recommended therapy | Placebo |
| A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19) | ChiCTR2000029837 | Moderate | Phosphoric chloroquine BID + recommended therapy | Placebo + recommended therapy |
| Study for convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19) | ChiCTR2000029850 | Severe | Standardized comprehensive treatment combined with convalescent plasma treatment | Standardized comprehensive treatment |
| A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19) | ChiCTR2000029853 | Moderate | Oral administration of 5 tablets of 1mg Azvudine tablets daily | Recommended treatment |
| Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a multicenter, randomized controlled trial | ChiCTR2000029868 | Moderate | Standard treatment + Day 1 to day 3: oral hydroxychloroquine sulfate tablets (100mg / tablet), 4 tablets each time, 3 times a day; Day 4 to day 14: oral hydroxychloroquine sulfate tablets (100mg / tablet), 4 tablets each time, 2 times a day. | Conventional treatment |
| A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19) | ChiCTR2000029935 | Moderate or severe | Conventional treatment combined with Chloroquine Phosphate | No |
| A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)  | ChiCTR2000029939 | Moderate or severe | Conventional treatment combined with Chloroquine Phosphate. | Conventional treatment |
| Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) | ChiCTR2000029988 | Severe | Chloroquine Phosphate | No intervention |
| A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19) | ChiCTR2000029989 | Moderate | Recombinant Human Interferon α1b Eye Drops | Placebo drop |
| Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19) | ChiCTR2000029990 | Moderate or severe | Mesenchymal stem cells | Saline placebo |
| A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19) | ChiCTR2000029992 | Severe | •Chloroquine phosphate1.0gx2 days for the first dose, 0.5gx12 day from the third day•Hydroxychloroquine sulfate 0.2g bid x 14 days | Routine treatment group |
| A randomized, open-label, controlled trial for the efficacy and safety of Favipiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19) | ChiCTR2000029996 | Moderate or severe | Favipiravir(High dose Medium dose Tablets; 200mg; orally; twice a day; The adult dose is 1800 mg per time on first day; the duration of treatment will be 10 d. Low dose Tablets; 200mg; oral; twice a day; The adult dose is 1600 mg per time on first day; the duration of treatment will be 10 d.) | Tablets; 200mg; oral; twice a day; The adult dose is 2400 mg per time on first day; the duration of treatment will be 10 d. |
| The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial | ChiCTR2000030001 | Moderate or severe | Basic treatment combined Triazavirin | Basic treatment combined Triazavirin placebo |
| Clinical study of novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus pneumonia (COVID-19) | ChiCTR2000030002 | Moderate or severe | Conventional therapy and Tranilast | Conventional therapy |
| A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19) | ChiCTR2000030006 | Moderate or severe | Ozonated autohemotherapy | Standard medical treatment |
| Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19) | ChiCTR2000030007 | Moderate or severe | rhG-CSF, 5ug/kg, combined with standard treatment | standard treatment |
| A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19) | ChiCTR2000030010 | Severe | Anti-SARS-CoV-2 virus inactivated plasma | Ordinary plasma |
| The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19) | ChiCTR2000030020 | Moderate or severe | Mesenchymal stem cells therapy | No |
| Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19) | ChiCTR2000030028 | Severe | PD-1 mAb + Standard treatment | Standard |
| A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19) | ChiCTR2000030029 | Moderate | Suramin IV | NR |
| A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)  | ChiCTR2000030031 | Moderate | 2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5) | 2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5) |
| Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19) | ChiCTR2000030039 | Moderate or severe | Conventional therapy with Infusion of convalescent plasma: 200-500ml, two infusions are recommended | Conventional therapy |
| A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19) | ChiCTR2000030046 | Moderate | Anti-2019-nCoV virus inactivated plasma | No |
| A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19) | ChiCTR2000030054 | Moderate or severe | •Hydroxychloroquine sulfate 0.2g bid x 14 days a day•The first dose of chloroquine phosphate was 1gx2 days, and the third day was 0.5gx12 days | Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan |
| A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19) | ChiCTR2000030058 | Moderate | Oral leflunomide | Oral placebo |
| Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19) | ChiCTR2000030082 | Moderate | Experimental group: based on control group, dihydroartemisinin piperaquine tablets (each containing 40mg dihydroartemisinin and 320mg piperaquine 2 tablets, bid 7 days.  | Antiviral treatment was selected as: α-interferon (5 million U bid atomization ) + Ardibdol 0.2 tid, 7 days. |
| Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) | ChiCTR2000030088 | Severe | Iv injection of Wharton's Jelly mesenchymal stem cells (1×10^6/kg), cell suspension volume: 40ml | Iv 40ml saline |
| A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) | ChiCTR2000030089 | Severe | Conventional treatment and adalimumab | conventional treatment |
| Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir | ChiCTR2000030113 | Moderate or severe | Favipiravir | Ritonavir |
| Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19) | ChiCTR2000030116 | Severe | Different stem cell doses for 2 groups | NR |
| Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) | ChiCTR2000030138 | Moderate or severe | Intravenous injection of human umbilical cord mesenchymal stem cells (UC-MSC) | Routine treatment + placebo |
| Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19) | ChiCTR2000030165 | Moderate or severe | Conventional treatment and ozonated autohemotherapy | Conventional treatment |
| Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19) | ChiCTR2000030167 | Moderate | Conventional Treatment & Low Dose Recombinant Human Interleukin-2, i.m.(1 million IU per time, once another day, 3 times per week, 2 weeks) | Conventional Treatment + Placebo i.m.(once another day, 3 times per week, 2 weeks) |
| Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19) | ChiCTR2000030170 | Severe | Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade ≥3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive(2 groups : Severe COVID-19 / Acute exacerbation COVID-19) | NR |
| Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration | ChiCTR2000030173 | Moderate or severe | Umbilical cord mesenchymal stem cells | Conventional therapy |
| Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19) | ChiCTR2000030179 | Severe | Routine treatment + plasma treatment | Routine treatment |
| Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) | ChiCTR2000030187 | Moderate or severe | Lopinavir and Ritonavir Tablets | Routine symptomatic support treatment |
| A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)  | ChiCTR2000030196 | Moderate or severe | conventional therapy + tocilizumab | No |
| Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19) | ChiCTR2000030224 | Severe | Injecting Mesenchymal stem cells | Injecting normal saline |
| A randomized, open-controlled trial for farpiravir tablets in the treatment of novel coronavirus pneumonia (COVID-19) | ChiCTR2000030254 | Moderate or severe | Favipiravir tablets | Abidole tablets |
| Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial | ChiCTR2000030259 | Moderate | Danorevir sodium tablets,/ritonavir oral | Symptomatic treatment |
| A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19) | ChiCTR2000030261 | Moderate or severe | Aerosol inhalation of exosomes | Blank |
| Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19) | ChiCTR2000030262 | Moderate or severe | "Anti-viral drugs and type I interferon and inflammation inhibitor TFF2" Once for two days / Once for one day | "Control Group" |
| Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patients | ChiCTR2000030300 | Moderate or severe | Mesenchymal stem cells therapy | No |
| Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19) | NCT04288102 | Moderate or severe | Conventional treatment + 3 times of MSCs(body weight≥70Kg, 4.0\*10E7 cells per time; body weight<70Kg, 3.0\*10E7 cells per time) intravenously at Day 0, Day 3, Day 6). | Conventional treatment + Placebo: Saline containing 1% Human serum albumin (solution of MSC), 3 times (intravenously at Day 0, Day 3, Day 6) |
| Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19) | NCT04292899 | Severe | •Remdesivir 200 mg 5 days + Conventional therapy•Remdesivir 200 mg 10 days + Conventional therapy | NR |
| Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | NCT04292730 | Moderate | •Remdesivir 200 mg 5 days + Conventional therapy•Remdesivir 200 mg 10 days + Conventional therapy | Standard of Care  |
| Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus | NCT04293692 | Moderate or severe | UC-MSCs (4 times of 0.5\*10E6 UC-MSCs /kg body weight intravenously at Day1, Day3, Day5, Day7) + Conventional treatment | Placebo (4 times of Placebo intravenously at Day1, Day3, Day5, Day7) + Conventional treatment |
| Evaluation of Ganovo Danoprevir Combined With Ritonavir in the Treatment of Novel Coronavirus Infection | NCT04291729 | Moderate | •Danoprevir + ritonavir +/- Interferon atomization (Ganovo one tablet 100mg/tablet at a time, twice a day, up to 14 days. Ritonavir one tablet 100mg/tablet at a time, twice a day, up to 14 days. With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.)•Long acting interferon (Pegasys 180 μg, subcutaneous injection once a week.)•Recombinant cytokine gene-derived protein (Spray inhalation of Novaferon, 20 μg, twice a day, up to 14 days.)•Lopinavir + ritonavir (200 mg / 50 mg, per tablet, oral, 2 tablets at a time, twice a day, up to 14 days.) | Chinese medicines, up to 14 days + Spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days. |
| Efficacy and Safety of IFN-Î±2Î² in the Treatment of Novel Coronavirus Patients | NCT04293887 | Moderate or severe | Standard therapy + interferon therapy (recombinant human interferon α1β 10ug Bid was administered by nebulization for 10 days)  | Standard therapy + blank therapy |
| Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 | NCT04299152 | Severe | Stem Cell Educator-Treated Mononuclear Cells Apheresis  | Conventional treatment |

NR: not reported